220
Participants
Start Date
February 6, 2024
Primary Completion Date
July 31, 2026
Study Completion Date
December 31, 2026
HS-20093
Intravenous (IV) infusion of HS-20093 Q3W; Participants will receive continuous treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
RECRUITING
Liaoning Cancer Hospital, Shenyang
RECRUITING
The First Hospital of China Medical University, Shenyang
RECRUITING
Jiangyin People's Hospital, Wuxi
RECRUITING
Nantong Tumor Hospital, Nantong
RECRUITING
Anhui Provincial Cancer Hospital, Hefei
NOT_YET_RECRUITING
Affiliated Hospital of Jining Medical University, Jining
NOT_YET_RECRUITING
Jiangxi Provincial Tumor Hospital, Nanchang
NOT_YET_RECRUITING
Fujian Provincial Tumor Hospital, Fujian
RECRUITING
The 900th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army, Fuzhou
RECRUITING
Nanyang Central Hospital, Nanyang
RECRUITING
Tongji Hospital, affiliated with Tongji Medical College, Huazhong University of Science and Technology, Wuhan
NOT_YET_RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
RECRUITING
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang
RECRUITING
Tumour Hospital of Anyang city, Anyang
RECRUITING
The First Affiliated Hospital of Henan University of Science & Technology, Luoyang
RECRUITING
Guangdong Provincial People's Hospital, Guangzhou
RECRUITING
Sichuan Cancer Hospital&Institude, Sichuan Cancer Center,Affiliate Cancer Hospital Of University Of Electronic Science and Technology of China, Chengdu
RECRUITING
The Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi
RECRUITING
Harbin Medical University Cancer Hospital, Harbin
Hansoh BioMedical R&D Company
INDUSTRY